Protein therapeutics is a synthetically manufactured protein on a huge scale through genetically modified host cells which is useful in the treatment of chronic diseases such as cancer, diabetes and CVD. The higher efficiency of protein therapeutics with less side effects is boosting the protein therapeutics market. Protein therapeutics market growth is hampered by the adverse side effects in chronic diseases and cost of production.
Some of the major factors propelling the growth of the global protein therapeutics market is the vast increase in the rate of cases of a number of chronic diseases such as cardiovascular conditions, cancer, and diabetes. The market is also boosting due to the grown awareness among consumers regarding the high efficiency of protein therapeutics with the lower risk of side effects and the increased level of acceptance among end users. However, the market’s growth prospects are hindered due to the certain extent owing to the vast funds which are required for the research and develop efficient methods for studying complex biological systems that can simulate the target organs or tissues.
The global protein therapeutics market is segmented by therapeutic proteins and region. The global protein therapeutics market is segmented by therapeutic proteins into monoclonal antobodies (mAbs), Erythropoietin (EPO), Insulin, Interferon (IFN), Human Growth Hormone (HGH), Follicle Stimulating Hormone (FSH), Blood Clotting Factors. The global protein therapeutics market is segmented by region into North America, Latin America, Europe, Middle East & Africa and Asia Pacific.
The market is increasing its presence in the market by doing various market entry strategies which includes geographical expansions, acquisitions, collaborations, mergers, product launch, joint ventures, product development, product approval, business expansion, sales expansion. Some of the key players operating in the global protein therapeutics market are Johnson & Johnson, Eli Lilly & Company, Roche Group, Pfizer, Inc., Bristol Myers Squibb Co., Sanofi, Merck Sereno S.A. Amgen, Inc., and Novartis, AbbVie, Amgen, Baxter International, Biocon, Biodel, AstraZeneca, BioGenomics, Biopartners, Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche, Celltrion, Chugai Pharmaceutical, Diamyd Medical, Diasome Pharmaceuticals, Generex Biotechnology, DiaVacs, Dynavax Technologies, Eli Lilly, Anhui Anke Biotechnology, GeneScience Pharmaceuticals, Ferring Pharmaceuticals, Hualan Biological Engineering, Intas Pharmaceuticals, Ipsen, Teva Pharmaceutical Industries, JCR Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Thermalin Diabetes, LG Life Sciences, MacroGenics, MannKind, Oramed Pharmaceuticals, Osiris Therapeutics, Pfizer, Sandoz International, Sanofi, Tolerion, Wockhardt, and XOMA. There is a competitive analysis of the market by product type, by therapy area, and by protein function. There is detailed analysis done of the market based on geographical regions such as the Americas, APAC, and EMEA. On top of that, the manufacturers are concentrating more on the investments on the research in the field and the related developments occurring in the market. These activities are helpful in strengthening their goodwill in the ever competitive market. Also, they are focusing on acquiring local players especially in developing countries such as Russia, India, China, Netherlands, Indonesia, Denmark, Poland, New Zealand, Mexico, Argentina and Colombia among others.
The global protein therapeutics market is segmented
By Therapeutic Proteins:
• Monoclonal Antobodies (MABS)
• Erythropoietin (EPO)
• Interferon (IFN)
• Human Growth Hormone (HGH)
• Follicle Stimulating Hormone (FSH)
• Blood Clotting Factors
• North America
• Latin America
• Middle East & Africa
• Asia Pacific